iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Rhea-AI Summary
iBio (NASDAQ: IBIO) reported fiscal year 2026 results and a corporate update, highlighted by its transition to a clinical-stage company with the Phase 1 trial of IBIO-600, a long-acting anti-myostatin antibody. The single ascending dose phase dosed 31 of 32 participants across four cohorts with no safety findings that prevented dose escalation, and iBio is preparing multiple ascending dose escalation.
The company advanced obesity and cardiometabolic candidates IBIO-610 into IND-enabling studies and IBIO-800 into IND-enabling development, and in-licensed AstralBio’s amylin receptor antibody program. iBio closed an August 2025 public offering with potential gross proceeds up to $100 million and a $26 million private placement in January 2026, and entered a $100 million at-the-market facility. Revenues were $0.1 million versus $0.4 million in 2025; R&D expenses rose to $19.6 million, G&A was $10.6 million, and a $5.0 million intangible impairment was recorded. Net loss was $33.0 million, and cash, cash equivalents and debt securities totaled $88.0 million at June 30, 2026.
Positive
- Cash and investments of $88.0 million at June 30, 2026
- Net financing capacity with $26 million private placement and up to $100 million ATM
- Public offering with total potential gross proceeds up to $100 million in August 2025
- IBIO-600 Phase 1 single ascending dose completed 31 of 32 participants without dose-limiting safety findings
- IBIO-610 advanced into IND-enabling studies with supportive non-human primate and rodent data
- IBIO-800 moved into IND-enabling development after candidate selection and preclinical data
- Cash runway extended into fiscal year 2028, according to iBio
- New leadership with experienced CMO and board member additions in endocrinology and drug development
Negative
- Revenue decline to $0.1 million from $0.4 million year over year
- Operating loss widened to $35.1 million from $18.6 million
- Net loss increased to $33.0 million from $18.4 million
- R&D expenses rose to $19.6 million from $8.3 million, including a $2.5 million milestone
- $5.0 million impairment of an indefinite-lived intangible asset, IBIO-101
- Common shares outstanding increased to 55.7 million from 19.3 million, indicating dilution
News Explained
At June 30, iBio reported 55,698,561 shares outstanding; future ATM sales could dilute existing holders, but none are reported here.
The August 28 release reports an August 2025 public offering and January 2026 private placement as closed, while the Jefferies agreement permits future sales; common shares outstanding were
Issuing additional shares increases the total share count and reduces an existing holder’s percentage ownership absent offsetting changes.
The release describes the Jefferies facility as allowing sales of up to
The reported share count was 55,698,561 at
The next reported share count and any line item showing ATM shares or proceeds will clarify whether the authorized facility has begun adding shares.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Q3 FY26 earnings | Negative | -3.7% | Revenue was zero while R&D increased and cash runway extended into FY2028. |
| Feb 10 | Q2 FY26 earnings | Positive | -2.6% | $26 million PIPE financing extended the stated cash runway into Q3 FY2028. |
| Nov 12 | Q1 FY26 earnings | Positive | -8.0% | Public financing and preclinical data supported pipeline advancement and additional capital. |
| Sep 05 | FY2025 earnings | Positive | +2.9% | Pipeline progress, financing, Nasdaq transfer and improved revenue accompanied the annual results. |
| May 02 | Q3 FY2025 earnings | Negative | -1.9% | Net loss increased while R&D and G&A expenses rose year over year. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings events had an average 24-hour reaction of -2.68%, indicating a generally negative historical response.
Key Terms
pharmacokinetic medical
ind-enabling regulatory
cmc technical
monoclonal antibody medical
multiple ascending dose medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today announced its financial results for the fiscal year ended June 30, 2026, and provided a corporate update on its progress.
“Fiscal year 2026 was a transformative year for iBio, most importantly marked by our transition to a clinical-stage company with the initiation of the Phase 1 clinical trial of IBIO-600, a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition,” said Martin Brenner, Ph.D., DVM, Chief Executive Officer and Chief Scientific Officer of iBio. “Additional highlights came from our IBIO-610 program, where we presented preclinical data supporting its potential for fat-selective weight loss, complementing with current GLP-1 therapies by increasing fat loss while preserving lean mass, and to reduce weight regain following GLP-1 discontinuation. We are excited to build on this progress as we continue advancing our pipeline and working toward our mission of delivering transformative treatments to patients.”
Progress on Obesity and Cardiometabolic Pipeline
- Advanced IBIO-610, iBio’s long-acting Activin E antibody, into IND-enabling studies. In obese non-human primates, a single dose produced near-complete suppression of active Activin E for up to eight weeks and demonstrated a prolonged pharmacokinetic profile supporting the potential for infrequent dosing. Additional preclinical studies in rodents demonstrated fat-selective weight loss, additive weight loss and enhanced body-composition effects in combination with semaglutide, and prevention of weight regain following GLP-1 discontinuation. These data support IBIO-610’s potential as a differentiated treatment for obesity and related cardiometabolic diseases.
- Advanced IBIO-600, iBio’s long-acting myostatin antibody, through the single ascending dose portion of its first-in-human Phase 1 clinical trial, dosing 31 of the 32 planned participants across all four planned cohorts with no safety findings identified that precluded dose escalation. IBIO-600 is being developed to preserve muscle and improve body composition, including as a potential complement to GLP-1-based therapies. iBio is now preparing to advance IBIO-600 into the multiple ascending dose escalation portion of the clinical trial.
- Advanced IBIO-800, iBio’s myostatin × Activin A bispecific antibody, into IND-enabling development following selection of a development candidate. iBio initiated CMC and IND-enabling nonclinical development and presented preclinical data supporting its potential to preserve and increase muscle and address cardiopulmonary disease, with an initial focus on pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).
- In-licensed all rights to AstralBio’s amylin receptor antibody program that includes a portfolio of next-generation antibody agonists designed to achieve differentiated receptor pharmacology. The program includes selective AMY1 and AMY3 receptor agonists, selective amylin receptor agonists targeting both AMY1 and AMY3, and dual amylin and calcitonin receptor agonists. Candidates are advancing through preclinical characterization to identify the pharmacologic profiles best suited to the treatment of obesity and metabolic disease.
Corporate Developments
Financing and Capital Resources
- Closed a public offering in August 2025 for total potential gross proceeds of up to
$100 million (assuming the exercise of all of the warrants sold in the offering in full for cash), led by Balyasny Asset Management with participation from Cormorant Asset Management, Adage Capital Partners, Ally Bridge Group, Marshall Wace, Coastlands Capital, SilverArc Capital Management, Vestal Point Capital, and Ausangate Capital. - Closed a
$26 million private placement in January 2026 with healthcare-focused institutional investors led by Frazier Life Sciences, along with participation from other existing investors. - Entered into an Open Market Sale AgreementSM™ with Jefferies LLC providing for the sale, from time to time, of up to
$100 million of shares of iBio common stock.
Leadership Updates
- Strengthened the Board with the appointment of Elizabeth Stoner, M.D., who brings deep biotechnology industry experience and expertise in capital markets and clinical-stage drug development.
- Appointed Molly Carr, M.D. as iBio’s Chief Medical Officer, bringing more than 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic diseases to lead iBio’s global clinical strategy, medical affairs and regulatory initiatives.
“In the last fiscal year, we paired significant scientific progress with disciplined financial execution, substantially strengthening iBio’s balance sheet as we advanced our pipeline into clinical development,” said Felipe Duran, Chief Financial Officer. “Our successful financings, which extended our cash runway into fiscal year 2028, together with the addition of highly experienced leaders to our Board and management team, provide a strong foundation to execute on our clinical programs and translate continued scientific progress into meaningful value for patients and shareholders.”
Financial Results:
Revenues for the fiscal year ended June 30, 2026, were approximately
Research and Development (“R&D”) expenses for the fiscal year ended June 30, 2026, and June 30, 2025, were approximately
General and Administrative expenses for the fiscal year ended June 30, 2026, and June 30, 2025, were approximately
Impairment of Indefinite-Lived Intangible Assets for the fiscal year ended June 30, 2026, was approximately
iBio held cash and cash equivalents and investments in debt securities of approximately
About iBio, Inc.
iBio (Nasdaq: IBIO) is a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat diseases. Combining advanced antibody engineering with AI-driven discovery, iBio is advancing a differentiated pipeline designed to deliver sustained therapeutic effects and address significant unmet medical needs. iBio’s mission is to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine.
For more information, visit www.ibioinc.com or follow us on LinkedIn.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding IBIO-600 potentially being a best-in-class, long-acting anti-myostatin monoclonal antibody to preserve muscle and improve body composition; IBIO-610’s potential for fat-selective weight loss, complementing GLP-1 therapy by increasing fat loss while preserving lean mass, and reducing weight regain following GLP-1 discontinuation; iBio continuing to advance its pipeline and working toward its mission of delivering transformative treatments to patients; the potential for infrequent dosing of IBIO-610, iBio’s long-acting Activin E antibody; preclinical studies of IBIO-610 supporting its potential as a differentiated treatment for obesity and related cardiometabolic diseases; the four planned cohorts of the IBIO-600 Phase 1 clinical trial; the potential to move IBIO-600 into multiple ascending dose portion of the clinical trial; the potential of IBIO-600 to preserve muscle and improve body composition, including as a potential complement to GLP-1-based therapies; the potential of IBIO-800 to preserve and increase muscle and address cardiopulmonary disease; the assumed exercise of all of the warrants sold in the August 2025 public offering in full for cash; Dr. Carr leading the company’s global clinical strategy, medical affairs, and regulatory initiatives; the company advancing its obesity and cardiometabolic pipeline toward and into clinical development; the addition of highly experienced leaders to iBio’s Board and management team, together with its successful financings, providing a strong foundation to continue translating scientific progress into meaningful clinical and corporate value; iBio’s differentiated pipeline delivering sustained therapeutic effects and addressing significant unmet medical needs; and iBio’s ability to transform drug discovery, accelerate development timelines, and unlock new possibilities in precision medicine. While iBio believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, iBio’s ability to obtain regulatory approvals for commercialization of its product candidates, or to comply with ongoing regulatory requirements; regulatory limitations relating to iBio’s ability to promote or commercialize its product candidates for specific indications; acceptance of iBio’s product candidates in the marketplace and the successful development, marketing or sale of products; whether iBio will incur unforeseen expenses or liabilities or other market factors; and the other factors discussed in iBio’s filings with the SEC including its Annual Report on Form 10-K for the year ended June 30, 2026. The information in this release is provided only as of the date of this release, and iBio undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.
Corporate Contact:
iBio, Inc.
Investor Relations
ir@ibioinc.com
Media Contacts:
Ignacio Guerrero-Ros, Ph.D., or David Schull
Russo Partners, LLC
Ignacio.guerrero-ros@russopartnersllc.com
David.schull@russopartnersllc.com
(858) 717-2310 or (646) 942-5604
| iBio, Inc. and Subsidiaries | ||||||||
| Consolidated Statements of Operations and Comprehensive Loss | ||||||||
| (In Thousands, except per share amounts) | ||||||||
| Year Ended | ||||||||
| June 30, | ||||||||
| 2026 | 2025 | |||||||
| Revenue | $ | 100 | $ | 400 | ||||
| Operating expenses: | ||||||||
| Research and development | 19,643 | 8,312 | ||||||
| General and administrative | 10,595 | 10,690 | ||||||
| Impairment of indefinite-lived intangible asset | 5,003 | — | ||||||
| Total operating expenses | 35,241 | 19,002 | ||||||
| Operating loss | (35,141 | ) | (18,602 | ) | ||||
| Other income (expense): | ||||||||
| Interest income | 2,150 | 437 | ||||||
| Interest expense | (53 | ) | (212 | ) | ||||
| Total other income | 2,097 | 225 | ||||||
| Net loss before income taxes | (33,044 | ) | (18,377 | ) | ||||
| Income tax expense | — | — | ||||||
| Net loss | $ | (33,044 | ) | $ | (18,377 | ) | ||
| Comprehensive loss: | ||||||||
| Net loss | $ | (33,044 | ) | $ | (18,377 | ) | ||
| Other comprehensive loss - unrealized loss on debt securities | (45 | ) | — | |||||
| Comprehensive loss | $ | (33,089 | ) | $ | (18,377 | ) | ||
| Loss per common share - basic and diluted | $ | (0.32 | ) | $ | (1.75 | ) | ||
| Weighted-average common shares outstanding - basic and diluted - see Note 17 | 104,060 | 10,499 | ||||||
| iBio, Inc. and Subsidiaries | ||||||||
| Consolidated Balance Sheets | ||||||||
| (In Thousands, except share and per share amounts) | ||||||||
| June 30, | June 30, | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 56,395 | $ | 8,582 | ||||
| Accounts receivable - trade, net of allowance for credit losses of June 30, 2025, respectively | — | — | ||||||
| Investments in debt securities (adjusted cost respectively - see Note 6) | 31,644 | — | ||||||
| Subscription receivable | — | 105 | ||||||
| Promissory note receivable and accrued interest | 1,104 | — | ||||||
| Prepaid expenses and other current assets | 3,078 | 1,034 | ||||||
| Total Current Assets | 92,221 | 9,721 | ||||||
| Restricted cash | 228 | 210 | ||||||
| Promissory note receivable and accrued interest | — | 1,098 | ||||||
| Finance lease right-of-use assets, net of accumulated amortization | — | 68 | ||||||
| Operating lease right-of-use asset, net of accumulated amortization | 1,667 | 2,051 | ||||||
| Fixed assets, net of accumulated depreciation | 3,086 | 3,163 | ||||||
| Intangible assets, net of accumulated amortization | 1,825 | 6,848 | ||||||
| Prepaid expenses - noncurrent | 73 | — | ||||||
| Security deposits | 10 | 26 | ||||||
| Total Assets | $ | 99,110 | $ | 23,185 | ||||
| Liabilities and Stockholders' Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 4,423 | $ | 2,188 | ||||
| Accrued expenses | 5,626 | 1,345 | ||||||
| Finance lease obligations | — | 53 | ||||||
| Operating lease obligation - current portion | 546 | 490 | ||||||
| Equipment financing payable - current portion | — | 64 | ||||||
| Term promissory note | — | 766 | ||||||
| Contract liabilities | 1,150 | 1,200 | ||||||
| Total Current Liabilities | 11,745 | 6,106 | ||||||
| Operating lease obligation - net of current portion | 1,652 | 2,199 | ||||||
| Total Liabilities | 13,397 | 8,305 | ||||||
| Stockholders' Equity | ||||||||
| Preferred Stock - | — | — | ||||||
| Common Stock - issued and outstanding as of June 30, 2026 and June 30, 2025, respectively | 56 | 19 | ||||||
| Additional paid-in capital | 450,970 | 347,085 | ||||||
| Accumulated other comprehensive loss | (45 | ) | — | |||||
| Accumulated deficit | (365,268 | ) | (332,224 | ) | ||||
| Total Stockholders’ Equity | 85,713 | 14,880 | ||||||
| Total Liabilities and Stockholders' Equity | $ | 99,110 | $ | 23,185 | ||||
